These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 37576545)

  • 21. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
    Lee YH; Lin PL; Chiou WR; Huang JL; Lin WY; Liao CT; Chung FP; Liang HW; Hsu CY; Chang HY
    ESC Heart Fail; 2021 Apr; 8(2):1204-1215. PubMed ID: 33410280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction.
    Gori M; Januzzi JL; D'Elia E; Lorini FL; Senni M
    Card Fail Rev; 2021 Mar; 7():e06. PubMed ID: 33889425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
    Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
    JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues.
    Itier R; Guillaume M; Ricci JE; Roubille F; Delarche N; Picard F; Galinier M; Roncalli J
    ESC Heart Fail; 2021 Apr; 8(2):789-798. PubMed ID: 33534958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
    Escobar C; Luis-Bonilla J; Crespo-Leiro MG; Esteban-Fernández A; Farré N; Garcia A; Nuñez J
    Expert Opin Pharmacother; 2022 Oct; 23(14):1589-1599. PubMed ID: 35995759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
    Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction.
    Al-Mohammad A
    ESC Heart Fail; 2019 Aug; 6(4):878-883. PubMed ID: 31119890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.
    Jia R; Ji Y; Sun D
    Biomed Pharmacother; 2022 Nov; 155():113701. PubMed ID: 36116249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
    Amin OA; Alaarag AF
    Anatol J Cardiol; 2021 Mar; 25(3):163-169. PubMed ID: 33690130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence.
    Koufou EE; Arfaras-Melainis A; Rawal S; Kalogeropoulos AP
    J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33429888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction.
    Minhas AMK; Bhopalwala HM; Dewaswala N; Salah HM; Khan MS; Shahid I; Biegus J; Lopes RD; Pandey A; Fudim M
    Curr Probl Cardiol; 2023 Aug; 48(8):101199. PubMed ID: 35405161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction and Coexisting End-Stage Renal Disease.
    Lin WY; Shao YJ; Chiang AF; Huang CC; Chiang KF; Chan CS; Huang CY; Hsiao BY
    Clin Pharmacol Ther; 2024 Aug; 116(2):471-477. PubMed ID: 38880970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis.
    Mo X; Lu P; Yang X
    Clin Cardiol; 2023 Oct; 46(10):1137-1145. PubMed ID: 37465885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction.
    McDonald M; Virani S; Chan M; Ducharme A; Ezekowitz JA; Giannetti N; Heckman GA; Howlett JG; Koshman SL; Lepage S; Mielniczuk L; Moe GW; O'Meara E; Swiggum E; Toma M; Zieroth S; Anderson K; Bray SA; Clarke B; Cohen-Solal A; D'Astous M; Davis M; De S; Grant ADM; Grzeslo A; Heshka J; Keen S; Kouz S; Lee D; Masoudi FA; McKelvie R; Parent MC; Poon S; Rajda M; Sharma A; Siatecki K; Storm K; Sussex B; Van Spall H; Yip AMC
    Can J Cardiol; 2021 Apr; 37(4):531-546. PubMed ID: 33827756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Bhattacharjee P; Khan Z
    Cureus; 2023 Nov; 15(11):e48674. PubMed ID: 38090453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.